Antineoplastic Agents, Immunological
-
Subject Areas on Research
-
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
-
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
-
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.
-
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
-
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
-
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
-
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
-
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
-
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
-
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
-
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.
-
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
-
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
-
Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
-
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
-
Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
-
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
-
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
-
Bevacizumab biosimilars: scientific justification for extrapolation of indications.
-
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
-
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.
-
CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
-
Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer.
-
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
-
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
-
Checkpoint inhibitors in hematological malignancies.
-
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
-
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
-
Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
-
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
-
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
-
Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
-
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
-
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
-
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
-
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
-
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
-
Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.
-
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.
-
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
-
Endoglin Targeting: Lessons Learned and Questions That Remain.
-
Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
-
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
-
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
-
Health-related quality of life measures and immune checkpoint inhibitors: A systematic review.
-
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
-
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
-
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.
-
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
-
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
-
Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
-
Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab.
-
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
-
Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.
-
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
-
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
-
Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.
-
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
-
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
-
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
-
Injectable Therapies for Regional Melanoma.
-
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
-
Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
-
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.
-
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
-
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
-
Management of Immunotherapy-Related Toxicities, Version 1.2019.
-
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
-
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
-
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
-
Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
-
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
-
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
-
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
-
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
-
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
-
New agents and regimens for diffuse large B cell lymphoma.
-
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
-
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
-
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
-
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
-
Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
-
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
-
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
-
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
-
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
-
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
-
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
-
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
-
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
-
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.
-
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
-
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
-
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.
-
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
-
Preclinical and Coclinical Studies in Prostate Cancer.
-
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
-
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
-
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
-
Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
-
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
-
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
-
Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
-
Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
-
Retreatment with talimogene laherparepvec for advanced melanoma.
-
Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.
-
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
-
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
-
Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.
-
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
-
Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
-
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
-
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
-
Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
-
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
-
The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
-
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
-
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
-
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
-
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
-
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
-
Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.
-
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
-
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.
-
Updates on Merkel Cell Carcinoma.
-
Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.